Erytech Pharma SA
PAR:ERYP
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is ERYP's stock price target?
Not Available
ERYP doesn't have any price targets made by Wall Street professionals.
What is Erytech Pharma SA's Revenue forecast?
Projected CAGR
-39%
For the last 1 year the compound annual growth rate for Erytech Pharma SA's revenue is 59%. The projected CAGR for the next 3 years is -39%.